How does glioblastoma kill you

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 8, 2026

Quick Answer: Glioblastoma kills primarily by causing progressive neurological dysfunction as the tumor infiltrates and compresses critical brain structures. The median survival time is only 12-15 months with standard treatment, and less than 5% of patients survive beyond 5 years. Death typically results from increased intracranial pressure, brain herniation, or loss of vital functions controlled by affected brain regions, with most patients succumbing within 2 years of diagnosis.

Key Facts

Glioblastoma accounts for approximately 14.9% of all primary brain tumors
The median survival time is 12-15 months with standard treatment
Only 6.8% of patients survive 5 years after diagnosis
Standard treatment includes surgical resection followed by radiation and temozolomide chemotherapy
The tumor typically recurs within 6-9 months after initial treatment

Overview

Glioblastoma multiforme (GBM) is the most aggressive and common malignant primary brain tumor in adults, representing approximately 14.9% of all primary brain tumors and 48.3% of malignant brain tumors. First described in detail by neuropathologists Harvey Cushing and Percival Bailey in the 1920s, glioblastoma was historically called glioblastoma multiforme due to its varied microscopic appearance. The World Health Organization classifies it as a Grade IV astrocytoma, the highest malignancy grade. Incidence rates are approximately 3.21 cases per 100,000 population in the United States, with about 12,000 new cases diagnosed annually. The tumor typically affects adults between 45-70 years old, though it can occur at any age, with a slight male predominance (1.6:1 male-to-female ratio). Diagnosis relies on MRI imaging showing characteristic ring-enhancing lesions with central necrosis, confirmed by histopathological examination revealing pseudopalisading necrosis and microvascular proliferation.

How It Works

Glioblastoma kills through multiple interconnected mechanisms that disrupt normal brain function. The tumor's rapid growth and infiltrative nature cause direct compression of surrounding brain tissue, leading to increased intracranial pressure that can result in brain herniation - a fatal event where brain tissue shifts into compartments it shouldn't occupy. Tumor cells secrete vascular endothelial growth factor (VEGF), promoting abnormal blood vessel formation that often leaks, causing cerebral edema. The blood-brain barrier becomes disrupted, allowing fluid accumulation that further increases pressure. As the tumor infiltrates functional brain areas, it disrupts neural circuits controlling vital functions like breathing, heart rate, and consciousness. The tumor's metabolic demands also create a hypoxic environment that promotes necrosis and releases inflammatory cytokines, causing additional tissue damage. Treatment resistance develops quickly due to tumor heterogeneity and the presence of glioma stem cells that survive conventional therapies.

Why It Matters

Glioblastoma represents one of oncology's most challenging problems due to its devastating prognosis and limited treatment options. Despite decades of research, survival rates have improved only modestly since the 2005 introduction of temozolomide chemotherapy. The disease carries enormous human and economic costs, with patients experiencing progressive neurological decline that often requires full-time caregiving. Research into glioblastoma has advanced our understanding of cancer biology, particularly regarding tumor heterogeneity, treatment resistance, and the tumor microenvironment. Current clinical trials explore immunotherapy, targeted therapies, tumor-treating fields, and novel drug delivery methods. The disease's impact extends beyond patients to families and healthcare systems, highlighting the urgent need for better treatments and emphasizing why brain tumor research remains a critical priority in medical science.